Safety and Biomarker Responses of Delgocitinib (JAK1,2,3/TYK2 Inhibitor) in Central Centrifugal Cicatricial Alopecia and Lichen Planopilaris

Abroad (travel likely)RecruitingPHASE2

Conditions

Central Centrifugal Cicatricial Alopecia · Lichen Planopilaris

Simple summaryAI-assisted

This summary is produced by a language model and is experimental. It may be incomplete or inaccurate and is not a substitute for professional medical advice.

Locations

Icahn School of Medicine at Mount Sinai, New York, New York, United States
Contact: Study coordinator (Giselle Singer) · giselle.singer@mssm.edu · 212-241-3288
Contact: Principal Investigator (Benjamin Ungar)

Study leads

Benjamin Ungar, MD
Principal Investigator
Icahn School of Medicine at Mount Sinai

View source on ClinicalTrials.gov

Similar trials

Other trials that are currently recruiting and may be relevant based on condition, treatment, phase, or location

Deucravacitinib in the Treatment of Cicatricial Alopecias

Central Centrifugal Cicatricial Alopecia · Frontal Fibrosing Alopecia

Abroad (travel likely)RecruitingPHASE2

New York, United States

A Pilot Study of Revian Red All LED Cap as a Novel Treatment for Central Centrifugal Cicatricial Alopecia

Central Centrifugal Cicatricial Alopecia

Abroad (travel likely)Recruiting

Winston-Salem, United States

Treatment Results for Patients With Central Centrifugal Cicatricial Alopecia (CCCA): a Multicenter Prospective Study

Central Centrifugal Cicatricial Alopecia (CCCA)

Abroad (travel likely)RecruitingPHASE4

Winston-Salem, United States